Latest Diagnostics News

Universal Biosensors updates investors on a shift from a secured loan to a potential entitlement offer, signaling evolving funding strategies and extended timelines.

Atomo Diagnostics has secured a US$410,000 order from Lumos Diagnostics for its Pascal test cassettes, following Lumos's exclusive six-year US distribution deal for the FebriDx test with PHASE Scientific.

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

Imagion Biosystems has raised A$3.5 million through a placement to fund its Phase 2 clinical trial for HER2+ Breast Cancer in the US, marking a significant step in advancing its proprietary MagSense® imaging technology.

Rhythm Biosciences has advanced its ColoSTAT® diagnostic kits to final production validation, demonstrating consistent detection of colorectal cancer across all stages in a pivotal study. The company is gearing up for regulatory submission and commercial launch later this year.

Waratah Minerals has significantly expanded the Spur Gold Corridor with high-grade gold mineralisation, revealing new zones of visible gold and advancing copper-gold exploration at its flagship Spur Project in New South Wales.

Pacific Edge has successfully closed its Share Purchase Plan, raising $4.7 million and bringing total new equity to $20.7 million, surpassing initial targets. The capital raise awaits shareholder approval at the upcoming Annual Meeting.

Babylon Pump & Power has completed two key acquisitions, expanding its water services platform and enhancing earnings with minimal integration risk. These moves position the company for sustained growth in the mining services sector.

Resmed Inc. reported a robust 10% revenue increase and a 19% rise in operating profit for fiscal 2025, alongside a 13% dividend hike, driven by strong demand for sleep and breathing health devices and growth in digital health software.

Pro Medicus Limited has entered a strategic financing arrangement with 4DMedical to accelerate the development and commercialization of cutting-edge lung function imaging software.

4DMedical has landed a $10 million strategic investment from Pro Medicus, aimed at accelerating its commercial growth and advancing its CT – VQ™ technology towards FDA clearance in the US.

4DMedical reports a 56% revenue surge in FY25 alongside a strategic $10 million investment from Pro Medicus, advancing its CT, VQ™ lung imaging technology towards FDA clearance.